254 related articles for article (PubMed ID: 27329511)
1. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
Dávila-Seijo P; Dauden E; Carretero G; Ferrandiz C; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Llamas M; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2016 Nov; 30(11):1942-1950. PubMed ID: 27329511
[TBL] [Abstract][Full Text] [Related]
2. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
Belinchón I; Ramos JM; Carretero G; Ferrándiz C; Rivera R; Daudén E; De la Cueva-Dobao P; Gómez-García FJ; Herrera-Ceballos E; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Llamas-Velasco M; Ortiz PL; García-Doval I; Descalzo MA;
J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1700-1708. PubMed ID: 28485816
[TBL] [Abstract][Full Text] [Related]
3. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G; Ferrandiz C; Dauden E; Vanaclocha Sebastián F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina-Gibert M; López-Estebaranz JL; Ferrán M; Torrado R; Carrascosa JM; Carazo C; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):156-63. PubMed ID: 24684267
[TBL] [Abstract][Full Text] [Related]
4. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
[No Abstract] [Full Text] [Related]
5. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
Egeberg A; Ottosen MB; Gniadecki R; Broesby-Olsen S; Dam TN; Bryld LE; Rasmussen MK; Skov L
Br J Dermatol; 2018 Feb; 178(2):509-519. PubMed ID: 29094341
[TBL] [Abstract][Full Text] [Related]
7. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
8. Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-term drug-survival study from the BioCAPTURE registry.
Zweegers J; van den Reek JM; van de Kerkhof PC; Otero ME; Kuijpers AL; Koetsier MI; Arnold WP; Berends MA; Weppner-Parren L; Ossenkoppele PM; Njoo MD; Mommers JM; van Lümig PP; Driessen RJ; Kievit W; de Jong EM
Br J Dermatol; 2016 Aug; 175(2):340-7. PubMed ID: 26989852
[TBL] [Abstract][Full Text] [Related]
9. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
[TBL] [Abstract][Full Text] [Related]
10. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
[TBL] [Abstract][Full Text] [Related]
11. Biologic drug survival in Israeli psoriasis patients.
Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
[TBL] [Abstract][Full Text] [Related]
12. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry.
Dávila-Seijo P; Dauden E; Descalzo MA; Carretero G; Carrascosa JM; Vanaclocha F; Gómez-García FJ; De la Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; López-Estebaranz JL; Alsina M; Sánchez-Carazo JL; Ferrán M; Torrado R; Ferrandiz C; Rivera R; Llamas M; Jiménez-Puya R; García-Doval I;
J Invest Dermatol; 2017 Feb; 137(2):313-321. PubMed ID: 27677836
[TBL] [Abstract][Full Text] [Related]
13. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
14. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C; Carretero G; Ferrandiz C; Dauden E; Vanaclocha F; Gómez-García FJ; Herrera-Ceballos E; De la Cueva-Dobao P; Belinchón I; Sánchez-Carazo JL; Alsina M; López-Estebaranz JL; Ferrán M; Carrascosa JM; Torrado R; Argila D; Rivera R; Jiménez-Puya R; García-Doval I;
J Eur Acad Dermatol Venereol; 2015 May; 29(5):858-64. PubMed ID: 25185962
[TBL] [Abstract][Full Text] [Related]
15. Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kalb RE; Fiorentino DF; Lebwohl MG; Toole J; Poulin Y; Cohen AD; Goyal K; Fakharzadeh S; Calabro S; Chevrier M; Langholff W; You Y; Leonardi CL
JAMA Dermatol; 2015 Sep; 151(9):961-9. PubMed ID: 25970800
[TBL] [Abstract][Full Text] [Related]
16. Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.
Lunder T; Zorko MS; Kolar NK; Suhodolcan AB; Marovt M; Leskovec NK; Marko PB
Int J Dermatol; 2019 Jun; 58(6):631-641. PubMed ID: 30973647
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
Daudén E; Carretero G; Rivera R; Ferrándiz C; Llamas-Velasco M; de la Cueva P; Belinchón I; Gómez-García FJ; Herrera-Acosta E; Ruiz-Genao DP; Ferrán-Farrés M; Alsina M; Baniandrés-Rodríguez O; Sánchez-Carazo JL; Sahuquillo-Torralba A; Fernández-Freire LR; Vilar-Alejo J; García-Donoso C; Carrascosa JM; Herrera-Ceballos E; López-Estebaranz JL; Botella-Estrada R; Segovia-Muñoz E; Descalzo MA; García-Doval I;
J Am Acad Dermatol; 2020 Jul; 83(1):139-150. PubMed ID: 32213306
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
19. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register.
Iskandar IY; Ashcroft DM; Warren RB; Yiu ZZ; McElhone K; Lunt M; Barker JN; Burden AD; Ormerod AD; Reynolds NJ; Smith CH; Griffiths CE
Br J Dermatol; 2015 Aug; 173(2):510-8. PubMed ID: 25989336
[TBL] [Abstract][Full Text] [Related]
20. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Carrascosa JM; Rivera N; Garcia-Doval I; Carretero G; Vanaclocha F; Daudén E; Gómez-García FJ; De-la-Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; Alsina M; Sánchez-Carazo JL; Ferrán M; Lopez-Estebaranz JL; Pérez-Zafrilla B; Llamas M; Rivera R; Ferrándiz C;
Actas Dermosifiliogr; 2015 Oct; 106(8):638-43. PubMed ID: 26141003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
